CoChat

Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis

Krausz, Sarah, Boumans, Maria J. H., Gerlag, Danielle M., Lufkin, Joelle, van Kuijk, Arno W. R., Bakker, Alian, de Boer, Maarten, Lodde, Beatrijs M., Reedquist, Kris A., Jacobson, Eric W., O'Meara, Michael, Tak, Paul P. · 2012 · Arthritis & Rheumatism
Cited by 85

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Objective: To investigate the safety, tolerability, pharmacokinetics, and efficacy of apilimod mesylate, an oral interleukin‐12 (IL‐12)/IL‐23 inhibitor, in patients with rheumatoid arthritis (RA). Methods: We performed a phase IIa, randomized, double‐blind, placebo‐controlled proof‐of‐concept study of apilimod, in combination with methotrexate, in 29 patients with active RA (3:1 ratio of apilimod‐treated to placebo‐treated patients) in 3 stages. Patients received apilimod 100 mg/day or placebo for 4 weeks (stage 1) or 8 weeks (stage 2). In stage 3, patients received apilimod 100 mg twice a day or placebo for 8 weeks, with an optional extension of 4 weeks. Clinical response (Disease Activity Score in 28 joints [DAS28] and American College of Rheumatology [ACR] criteria) was assessed throughout; synovial tissue samples collected at baseline and on day 29 (stages 1 and 2) or day 57 (stage 3) were stained for cellular markers and cytokines for immunohistochemistry analysis. Results: While only mild adverse events were observed in stages 1 and 2, in stage 3, all patients experienced headache and/or nausea. Among apilimod‐treated patients (100 mg/day), there was a small, but significant, reduction in the DAS28 on day 29 and day 57 compared with baseline. ACR20 response was reached in only 6% of patients on day 29 and 25% of patients on day 57, similar to the percentage of responders in the placebo group. Increasing the dosage (100 mg twice a day) did not improve clinical efficacy. Consistent with clinical results, apilimod did not have an effect on expression of synovial biomarkers. Of importance, we also did not observe an effect of apilimod on synovial IL‐12 and IL‐23 expression. Conclusion: Our results do not support the notion that IL‐12/IL‐23 inhibition by apilimod is able to induce robust clinical improvement in RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34339

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 85

Metadata

Authors
Krausz, S., Boumans, M. J. H., Gerlag, D. M., Lufkin, J., van Kuijk, A. W. R., Bakker, A., de Boer, M., Lodde, B. M., Reedquist, K. A., Jacobson, E. W., O'Meara, M., & Tak, P. P.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-05-25
Volume
64
Issue
6
Pages
1750-1755
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2061948993
Cited by
85
References
3
FWCI
2.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.34339
The paper
Krausz, S., Boumans, M. J. H., Gerlag, D. M., Lufkin, J., van Kuijk, A. W. R., Bakker, A., de Boer, M., Lodde, B. M., Reedquist, K. A., Jacobson, E. W., O'Meara, M., & Tak, P. P. (2012). Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.34339

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.